ProMIS Neurosciences, Inc. (PMN) Key Metrics
PMN valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $73.1M
- Enterprise value
- $65.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.25
PMN key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPMN returns How much profit the business earns on the capital it uses.
Return on assets−299.8 pts
−282.8%
2025 · hover or tap a bar for each year
20232025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20232025
PMN financial health Debt, liquidity and how easily interest is covered.
Net debt+$7.2M
−$6.2M
2025 · hover or tap a bar for each year
20232025
Current ratio−89.7%
0.88
2025 · hover or tap a bar for each year
20232025
PMN efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding
23 days
2025 · hover or tap a bar for each year
20232025
PMN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PMN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PMN key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Share price at fiscal year-end | $6.83 | $23.75 | $28.75 |
| Returns & profitability | |||
| Return on equity (ROE) | — | 27.5% | −466.4% |
| Return on assets (ROA) | −282.8% | 17.1% | −128.5% |
| Return on tangible assets | −432.6% | 14.7% | −128.5% |
| Income quality (OCF / net income) | — | −9.78 | — |
| Financial health | |||
| Cash & short-term investments | $6.2M | $13.3M | $12.6M |
| Net debt | −$6.2M | −$13.3M | −$12.6M |
| Net debt / EBITDA | — | −4.67 | — |
| Current ratio | 0.88 | 8.52 | 1.46 |
| Quick ratio | 0.88 | 8.52 | 1.46 |
| Interest coverage | — | -219.2 | -93.8 |
| Working capital | −$1.2M | $16.7M | $4.3M |
| Invested capital | −$7.4M | $3.2M | −$8.9M |
| Tangible asset value | −$1.3M | $16.5M | $3.8M |
| Net current asset value | −$1.3M | $16.5M | $3.8M |
| Capital allocation | |||
| Capex / depreciation | — | — | 0.00 |
| Efficiency | |||
| Days payables outstanding | 23.4 | — | 274.1 |
| Receivables turnover | 0.00 | 0.00 | 0.00 |
| Payables turnover | 15.59 | — | 1.33 |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average receivables | $57,278 | $78,336 | $78,637 |
| Average payables | $2.1M | $4.8M | $7.8M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from PMN's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PMN valuation and financial ratios
See the PMN income statement, the PMN chart for price history, or the PMN stock overview for the latest quote and news.
PMN key metrics FAQ
What is ProMIS Neurosciences's current ratio?
ProMIS Neurosciences's current ratio was 0.88 at the end of fiscal 2025: current assets were 0.88 times current liabilities.